Michael Petusky analyst BARRINGTON

Currently out of the existing stock ratings of Michael Petusky, 180 are a BUY (90.91%), 16 are a HOLD (8.08%), 2 are a SELL (1.01%).

Michael Petusky

Work Performance Price Targets & Ratings Chart

Analyst Michael Petusky works at BARRINGTON with a stock forecast success ratio of 62.17% fulfilled within 259.88 days on average.

Michael Petusky’s has documented 403 price targets and ratings displayed on 17 stocks. The coverage is on Healthcare, Consumer Defensive, Technology sectors.

Most recent stock forecast was given on VRME, VerifyMe at 24-May-2024.

Wall Street Analyst Michael Petusky

Analyst best performing recommendations are on VRME (VERIFYME).
The best stock recommendation documented was for VRME (VERIFYME) at 3/29/2023. The price target of $2 was fulfilled within 5 days with a profit of $0.43 (27.39%) receiving and performance score of 54.78.

Average potential price target upside

ANIK Anika Therapeutics HAE Haemonetics HSIC Henry Schein LMAT LeMaitre Vascular LNDC Landec MMSI Merit Medical Systems OPK Opko Health PRMW Primo Water Corp TVTY Tivity Health USPH US Physicalrapy XRAY Dentsply Sirona MODV ModivCare OPCH Option Care Health SRDX SurModics VAR Varian Medical Systems VRME VerifyMe PI Impinj

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

37

$12.43 (50.59%)

28

17 days ago

10/12 (83.33%)

$11.74 (46.48%)

110

Buy

32

$7.43 (30.24%)

61

9 months 17 days ago

1/3 (33.33%)

$11.99 (59.92%)

73

Hold

35

1 years 7 months 12 days ago

0/2 (0%)

$8.78 (33.49%)

Hold

46

$23.44 (103.90%)

46

2 years 6 months 8 days ago

0/2 (0%)

$5.44 (13.41%)

Buy

65

$40.43 (164.55%)

54

4 years 4 months 16 days ago

5/6 (83.33%)

$15.2 (30.52%)

21

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Michael Petusky is most bullish on?

Potential upside of $36.62 has been obtained for SRDX (SURMODICS)

Which stock is Michael Petusky is most reserved on?

Potential downside of -$0.75 has been obtained for LMAT (LEMAITRE VASCULAR)

What Year was the first public recommendation made by Michael Petusky?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?